181 related articles for article (PubMed ID: 25587300)
1. Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy.
Ali MS; Alam MS; Alam N; Siddiqui MR
Iran J Pharm Res; 2014; 13(4):1125-40. PubMed ID: 25587300
[TBL] [Abstract][Full Text] [Related]
2. Nanoemulsions as vehicles for transdermal delivery of aceclofenac.
Shakeel F; Baboota S; Ahuja A; Ali J; Aqil M; Shafiq S
AAPS PharmSciTech; 2007 Dec; 8(4):E104. PubMed ID: 18181525
[TBL] [Abstract][Full Text] [Related]
3. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
[TBL] [Abstract][Full Text] [Related]
4. A comparative
Ahmad N; Ahmad R; Mohammed Buheazaha T; Salman AlHomoud H; Al-Nasif HA; Sarafroz M
Saudi J Biol Sci; 2020 Apr; 27(4):1024-1040. PubMed ID: 32256163
[TBL] [Abstract][Full Text] [Related]
5. Stability studies of silymarin nanoemulsion containing Tween 80 as a surfactant.
Parveen R; Baboota S; Ali J; Ahuja A; Ahmad S
J Pharm Bioallied Sci; 2015; 7(4):321-4. PubMed ID: 26681893
[TBL] [Abstract][Full Text] [Related]
6. Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsions.
Shakeel F; Ramadan W
Colloids Surf B Biointerfaces; 2010 Jan; 75(1):356-62. PubMed ID: 19783127
[TBL] [Abstract][Full Text] [Related]
7. Investigation of true nanoemulsions for transdermal potential of indomethacin: characterization, rheological characteristics, and ex vivo skin permeation studies.
Shakeel F; Ramadan W; Ahmed MA
J Drug Target; 2009 Jul; 17(6):435-41. PubMed ID: 19527114
[TBL] [Abstract][Full Text] [Related]
8. Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy.
Ciríaco SL; Carvalho IPS; Alves Terceiro Neto J; de Sousa Lima Neto J; de Oliveira DHB; Cunha APGP; Cavalcante YTD; da Silva DTC; da Silva JA; Mineiro ALBB; de Lima Chagas Moreno Fernandes MZ; Carvalho ALM
Colloids Surf B Biointerfaces; 2020 Jan; 185():110573. PubMed ID: 31675643
[TBL] [Abstract][Full Text] [Related]
9. Development and Evaluation of Dutasteride Nanoemulgel for the Topical Delivery against Androgenic Alopecia.
Alam M; Mishra A; Yadav KS; Pradhan D; Kar B; Ghosh G; Rath G; Rai VK
Pharm Nanotechnol; 2024 Jan; ():. PubMed ID: 38173065
[TBL] [Abstract][Full Text] [Related]
10. Accelerated Stability Testing of a Clobetasol Propionate-Loaded Nanoemulsion as per ICH Guidelines.
Ali MS; Alam MS; Alam N; Anwer T; Safhi MM
Sci Pharm; 2013; 81(4):1089-100. PubMed ID: 24482775
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
[TBL] [Abstract][Full Text] [Related]
14. Nanoemulsion system for the transdermal delivery of a poorly soluble cardiovascular drug.
Dixit N; Kohli K; Baboota S
PDA J Pharm Sci Technol; 2008; 62(1):46-55. PubMed ID: 18402367
[TBL] [Abstract][Full Text] [Related]
15. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
16. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
Traish A; Haider KS; Doros G; Haider A
Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of skin cancer using low HLB surfactant nanoemulsion of 5-fluorouracil: a preliminary study.
Shakeel F; Haq N; Al-Dhfyan A; Alanazi FK; Alsarra IA
Drug Deliv; 2015; 22(4):573-80. PubMed ID: 24350612
[TBL] [Abstract][Full Text] [Related]
18. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
[TBL] [Abstract][Full Text] [Related]
20. Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.
Thomson A
Core Evid; 2005; 1(2):143-56. PubMed ID: 22500150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
